

Identification of inherited disease genes

Michel Koenig (EA_7042, Institut Universitaire de Recherche Clinique, Mpt)
michel.koenig@inserm.fr

Jean-Baptiste Rivière (Dpt Hospitalo-Universitaire de Génétique Moléculaire, Dijon)

- 09/14 The Revolution of the Human Genome Project/ Linkage Studies
- 09/21 Linkage studies for monogenic and multifactorial diseases
- 09/28 High-throughput sequencing and strategies for monogenic disease gene identification
- 10/05 Diseases by somatic and germline *de novo* mutations : concepts and investigation strategies (JB Rivière/M Koenig)




(simplified) history of DNA sequencing (part 1)

- 1977 Fred Sanger, "DNA sequencing with chain-terminating inhibitors" (radioactive electrophoresis on **plate** gels)
- 1984 Sequencing of the Epstein-Barr virus genome, 170,000 nt ...
- 1987 Applied Biosystems launches the first automated plate gel sequencers (**fluorescent** Sanger technique) ABI 370.
- 1995 Craig Venter et coll. (Institute for Genomic Research): first complete genome of a free-living organism, the bacterium *Haemophilus influenzae* (1,830,137 nt); first use of whole-genome shotgun sequencing.
- 1999 ABI introduces the 96 **capillary** sequencer (ABI Prism 3700) for the Human Genome Project (still fluo. Sanger)
- 2001 1st draft of the Human Genome Sequence (Sanger)
 - 2003 Completion of the Human Genome Project
- 2007 1st sequencing of an individual human genome Craig Venter (100 millions \$) (→ 2 million \$ in 2008)

Technological developments

Sanger sequencing :




Next generation sequencing or massively parallel sequencing 2nd generation : wash and scan (cycles) since 2004




3rd generation NGS : single molecule sequencing

Towards routine sequencing of entire human genomes (history of sequencing part 2)




The human genome

- Diploid organism, 23 pairs of chromosomes
- 3.3 billion pairs of nucleotide
- 60 % of repeated sequences
 - Interspersed seq. (retrotransposons [LINEs/SINEs], transposons) 45 %
 - Pseudogenes 1 %
 - Simple repeats (microsatellites) 3 %
 - Segmental duplications (non-homologous recombination) 5 %
 - Satellite sequences (recombination, tandem repeats) 6 %
- 2 % of protein coding sequences
- 20,687 genes and a mean 6.3 isoforms per locus.



Variation of the human genome

- **Mean variations, per individual :**
 - > 1 000 copy number variations (CNV)
 - 3 to 4 millions single nucleotide variations (SNV)
 - including \approx 20 000 in or near protein coding sequences :
 - 10 000 silent variations
 - 9 000 missense variations
 - 100 nonsense variations
 - 100 splice site variations
- Only about 10 variations are pathogenic = disease causing (genetic load)



The data deluge

Informatics and bioinformatics challenges




Identification of disease genes by family studies

Inherited diseases :

- Two or more affected per family
- Monogenic / multifactorial diseases
- Localisation of disease genes by linkage studies
- Calculation of likelihood of linkage: LOD score

Topics :

- Dominant diseases
- Recessive diseases
- Homozygosity mapping
- Founder effect




LOD score = $\log_{10} \frac{\text{Proba. to observe segregation of marker linked at distance } \theta}{\text{Proba. to observe segregation if not linked } (\theta = 0.50)}$

For $\theta = 0$, LOD score for the comparison the 2nd child with the 1st child :

$$= \log_{10} \frac{1}{1/2} = \log_{10} 2 = 0.3$$

LOD score for the comparison the 5 next children with respect to the 1st child:

$$= \log_{10} \frac{1^5}{(1/2)^5} = \log_{10} 2^5 = 5 \times 0.3 = 1.5$$




	probability in favor of linkage	probability by chance	Bonferoni correction for multiple testing x60
LOD score = 1.5	32 to 1 (2^5)	p=0.03	>1
<u>LOD score = 3</u>	1000 to 1 ($\approx 2^{10}$)	p=0.001	<u>p=0.06</u>
LOD score = 4	10 000 to 1 ($> 2^{13}$)	p=0.0001	p=0.006

Parkinson's disease pedigree

- Female
- Male
- Affected
- ⊘ Deceased
- + No offspring
- ◇ Unknown sex
- ⊞ No. of individuals]
- DNA samples analyzed
- I-XI Generations

I
II
III
IV
V
VI
VII
VIII
IX
X
XI




Recessive disease
for the 2nd affected child :

$$\text{LOD score} = \log_{10} \frac{1 \times 1}{1/2 \times 1/2} = \log_{10} 4 = 0.6$$

for the 1st healthy child :


$$\text{LOD score} = \log_{10} \frac{1/3}{1/4} = \log_{10} \frac{4}{3} = 0.125$$



Total LOD score for all children :

$$= \log_{10} 4 \times \frac{4^4}{3^4} = 0.6 + 4 \times 0.125 = 1.1$$

Linkage analysis by homozygosity mapping



Consanguinity









For the first affected child:

$$\text{LOD score} = \log_{10} \frac{1 \times 1}{1/2 \times 1/2} \times \frac{1 \times 1}{1/2 \times 1/2}$$


$$= \log_{10} 2^4 = 1.2$$


Total LOD score for all 4 affected children :

$$= \log_{10} 2^4 \times 4 \times 4 \times 4 = 1.2 + 3 \times 0.6 = 3.0$$



Multiallelic microsatellite marker DNTR dinucleotide tandem repeat






Ataxia with oculomotor apraxia type 2



Portuguese family - P13

Tunisian Family - Tun4



**Genotyping with
GeneChip Array 10K SNP
(single nucleotide
polymorphisms)
Affymetrix**

**(Actually GeneChip 250K
and 906K SNP)**








Figure 12
Example of Allele-Specific Hybridization with 40 probes / SNP

B **C**


I. Method: GeneChip array Affymetrix



Genomewide scan in a large consanguineous family




Coenzyme Q10 deficiency



Chromosome: 1 Sample: JLM_1688_10K


Probe Set	Chromosome	Physical Position	JLM_1684_10K Call	JLM_1684_10K LOH	JLM_1683_10K Call	JLM_1683_10K LOH	JLM_1686_10K Call	JLM_1686_10K LOH	JLM_1688_10K Call	JLM_1688_10K LOH	JLM_1687_10K Call	JLM_1687_10K LOH
681	SNP_A-1510203	216041421	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	1.48
682	SNP_A-1510239	216041496	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AA	1.48
683	SNP_A-1510222	216214296	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
684	SNP_A-1510869	216497313	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
685	SNP_A-1516407	216877367	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.14
686	SNP_A-1509797	217353869	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
687	SNP_A-1513688	217356078	NoCall	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AA	0.47
688	SNP_A-1513479	217705653	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.47
689	SNP_A-1514400	218136977	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
690	SNP_A-1510531	218143097	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
691	SNP_A-1512436	218809913	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
692	SNP_A-1512490	218809071	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
693	SNP_A-1507333	219135381	NoCall	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.24
694	SNP_A-1509403	219529663	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.24
695	SNP_A-1511940	219833559	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
696	SNP_A-1514260	219985330	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
697	SNP_A-1518174	221126285	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.69
698	SNP_A-1512418	221171487	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AA	0.69
699	SNP_A-1513846	221174780	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.69
700	SNP_A-1512671	222051072	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AA	0.69
701	SNP_A-1512799	223370406	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
702	SNP_A-1508029	223489960	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.36
703	SNP_A-1512893	223649081	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.36
704	SNP_A-1512754	224079709	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00
705	SNP_A-1514941	224757266	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.65
706	SNP_A-1518523	224807362	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	BB	0.65
707	SNP_A-1513157	224807653	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AA	0.65
708	SNP_A-1511741	225485567	BB	1.HJ	BB	15.02	BB	1.HJ	BB	1.HJ	AB	0.00
709	SNP_A-1519296	225498036	AA	1.HJ	AA	15.02	AA	1.HJ	AA	1.HJ	AB	0.00




HomoSNP Program

→ Homozygosity by descent shared by all 4 affected siblings on chromosome 1.


Founder effect (1)



Founder effect (2)




Variation of the length of a common shared region among patients, around the founder mutation



Founder effect

Geographical distribution, on the Portuguese mainland, of families with AOA1 (linked to 9p13)



families linked to 9p13



families with unknown linkage status



families not linked to 9p13

Founder haplotype for AOA1



AOAP4 AOAP11 AOAP7 AOAP1 AOAP5 AOAJ2 AOAJ1 AOAJ3

D9S1853	8 - 1	7 - 8	9	4	1	1	1	1
MS1 IRE-BP1	4 - 3	3 - 2	3	3	3	4	2	3
MS2 IRE-BP1	5 - 1	1 - 5	1	2	2	5	4	2
MS30	8	8 - 7	8	8	7	7	9	7
MS31	3	3 - 3	3	3	5	2	5	2
MS25	4	4 - 9	4	4	4	4	4	4
MD24	2	2	2	2	2	5	5	5
D9S1788	6	6	6	6	6	3	3	3
D9S1845	9	9	9	9	9	16	16	18
D9S165	11	11	11	11	11	10	10	11
MS26	7	7	7	7	7	5	5	5 - 9
MS28	3	3	3	3	3	3	3	3 - 4
MS21	3	3	3	3	2	3	3	2 - 4
D9S1878	14	14	14	14	6	5	5	5 - 14
D9S1817	12	12	12	12	13	16	16 - 13	16 - 15
D9S1805	3	3	3	3	3	4	4 - 4	4 - 5

AOA1 refined interval

Linkage disequilibrium


UCSC Genome Browser on Human May 2004 Assembly




Geographic origin of the 5 Algerian families linked to chr20 North-East of Algeria (Sétif wilaya)



PHARC syndrom (Polyneuropathy,
Hypoacusia, Ataxia, Retinitis P., Cataract)



Founder haplotype in
4 out of 5 families
linked to chr. 20




19601543	rs720436
20106062	rs1028434
20264206	rs928066
20287310	rs721424
20483833	rs1074440
20610543	D20S912
20826383	rs2038383
20930386	rs755963
21258407	D20S190
22854446	rs1888610
22923923	rs717756
22987041	rs2007743
23271987	rs1112819
23283569	D20S871
23295553	rs999072
23532116	rs726217
23570758	rs2254635
23573547	rs2145231
23937652	rs3843776
23937782	rs3843777
23937930	rs3848799
24033110	rs761863
24122028	rs487665
24371416	rs722834
24996940	rs2387577
24997283	rs2207631
25127155	rs2387733
26114910	D20S191
29310063	rs1474945
29469970	rs721220
29940293	D20S111
30429539	D20S200
31123410	DH1
31599059	D20S890
31929741	D20S878
31982015	rs725478
32000125	DH2
32309697	rs2378132
32325217	rs819144
32325488	rs819145
33431481	rs725908
33915657	D20S909
34316842	D20S847
34166072	rs3850528
35310424	rs1073768


	Alg 128	Alg 139	Alg 96	Alg 142	Alg 28
A	A	A	B	A	A
B	B	ND	B	B	B
B	B	ND	B	B	B
A	A	A	A	A	A
B	B	B	A	A	B
301	301	297	299	299	301
B	B	B	B	B	B
B	B	B	B	B	A
253	253	255	259	259	259
B	B	B	A	A	A
B	B	ND	A	A	A
A	A	ND	A	A	A
B	B	ND	B	B	B
194	194	190	194	194	194
B	B	B	A	A	A
A	A	A	B	B	B
B	B	ND	A	A	A
B	B	A	B	B	B
B	B	A	A	A	A
A	A	B	B	B	B
B	B	B	B	B	B
A	A	B	B	B	B
B	B	ND	B	B	B
A	A	A	A	A	A
227	227	229	229	229	229
B	B	B	B	B	B
A	A	A	A	A	A
249	249	251	251	251	251
283	283	271	271	271	271
263	263	267	265	265	ND
199	199	213	210	210	208
229	229	225	227	227	227
A	A	A	A	A	A
194	194	202	202	202	ND
A	A	A	A	A	B
A	A	A	A	A	A
B	B	B	B	B	A
A	A	ND	A	A	B
151	151	145	153	153	ND
157	157	153	151	ND	ND
A	A	B	A	A	A
A	A	B	A	A	A

CDK5RAP1
H470P


Homozygous mutation of the α/β hydrolase 12 (ABHD12) gene in 4 Algerian families




control



patient



carrier



Linkage for multifactorial diseases :

Same principles

(genetic linkage, linkage disequilibrium = association studies)

But very small penetrance

→ small LOD scores despite very large cohorts of patients

LOD score

